Table 1.

Patient characteristics

Characteristics	Median (range) or n (%)
Age at diagnosis, years	73.8 (60.9–88.8)
Gleason score at Dx	8 (6–9)
Time from diagnosis to CRPC, years	2.8 (0.7–17)
Time from CRPC to first lutetium treatment, years	2.3 (0.9–6.2)
Age at first lutetium, years	81.7 (75.1–91.9)
Number of treatment lines for mCRPC	4 (0–5)
Previous treatment with abiraterone	20 (83.3)
Response to abiraterone	9 (45)
Previous treatment with enzalutamide	20 (83.3)
Response to enzalutamide	11 (55)
Previous treatment with docetaxel	18 (75.0)
Response to docetaxel	14 (77.8)
Previous treatment with cabazitaxel	8 (33.3)
Response to cabazitaxel	3 (37.5)
Previous treatment with radium‐223	14 (58.3)
Response to radium‐223	6 (42.9)

Abbreviations: CRPC, castration‐resistant prostate cancer; Dx, diagnosis; mCRPC, metastatic CRPC.